Home Newsfeeds Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.

Brewing Competition Compels Paramount To Club Showtime Streaming Service With Paramount+

By Anusuya Lahiri

September 14, 7:44 AM

Paramount Global (NASDAQ:PARA) weighed aborting its Showtime streaming service and shifting its content into Paramount+, the Wall Street Journal reports.…

AMZN

HC Wainwright & Co. Reiterates Buy on IMV, Maintains $65 Price Target

By Benzinga Newsdesk

February 13, 10:50 AM

HC Wainwright & Co. analyst Joseph Pantginis reiterates IMV (NASDAQ:IMV) with a Buy and maintains $65 price target.

IMV

Highwoods Announces $40.2M Of Non-Core Asset Sales

By Happy Mohamed

May 31, 4:21 PM

Highwoods Properties, Inc. (NYSE:HIW) has sold One Independence Park, a 116,000 square foot office building in Tampa's Westshore BBD, for $19.5 million. One Independence Park is 100% occupied by a

HIW

Nio’s New ‘Anti-Shake’ AR Glasses Will Ensure A Smooth Movie Viewing Inside Moving Cars

By Bhavik Nair

September 5, 11:55 PM

Nio Inc (NYSE: NIO) has launched its augmented reality (AR) glasses, co-developed with AR device maker Nreal, now available for pre-order on the NIO App in China, the company said in a statement.

BABA

Jefferies Downgrades CytomX Therapeutics to Hold, Lowers Price Target to $2

Related Posts

Brewing Competition Compels Paramount To Club Showtime Streaming Service With Paramount+

HC Wainwright & Co. Reiterates Buy on IMV, Maintains $65 Price Target

Highwoods Announces $40.2M Of Non-Core Asset Sales

Nio’s New ‘Anti-Shake’ AR Glasses Will Ensure A Smooth Movie Viewing Inside Moving Cars